TICKERNERD
Menu
BBNXBBNXHealthcare · Medical Devices

BBNX Stock Forecast: Beta Bionics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$17
−3.60% on the day

The 13 Wall Street analysts covering Beta Bionics, Inc. hold a median 12-month price target of $24 — +34.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.0B
Ticker Nerd rank
37 / 100
Median analyst target
$24
Analysts covering
13
Revenue$32.0M+37.8% y/y
Operating income−$25.6M
Net income−$23.4M
Free cash flow−$15.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
−9.8%
YTD
−42.8%
1Y
−21.2%
From 52W high
−45.5%
From 52W low
+96.7%
$9
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beta Bionics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Growth
62
Accruals
56
Size
45
Value
41
Issuance
36
Quality
30
Momentum
30
Volatility
28

Revisions (72): Analysts have, on balance, been raising their forecasts.

Volatility (28): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BBNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26BBNXHigh $30Median $24Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
9 Buy4 Hold0 Sell
Low $16Median $24High $30

The green dot is the last close — the median target sits +34.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Truist SecuritiesMaintainsBuy$23 → $28
23 Sept 2026Wells FargoInitiatesOverweight$28
15 Sept 2026B of A SecuritiesMaintainsNeutral—
15 Sept 2026B of A SecuritiesMaintainsNeutral$18 → $20
15 Sept 2026BairdMaintainsNeutral$14 → $16
15 Sept 2026BairdMaintainsNeutral—
15 Sept 2026Truist SecuritiesReiteratesBuy$22 → $23
15 Sept 2026Truist SecuritiesReiteratesBuy—
14 Sept 2026Leerink PartnersMaintainsOutperform$24 → $27
14 Sept 2026Leerink PartnersMaintainsOutperform—
21 Aug 2026William BlairInitiatesMarket Perform—
21 Aug 2026William BlairInitiatesMarket Perform—
28 July 2026UBSAssumesBuy$22
15 July 2026Goldman SachsMaintainsBuy—
15 July 2026Goldman SachsMaintainsBuy$17 → $19
13 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026Truist SecuritiesMaintainsBuy$18 → $22
27 May 2026Goldman SachsMaintainsBuy—
18 May 2026B of A SecuritiesMaintainsNeutral—
22 Apr 2026Leerink PartnersMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BBNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Beta Bionics, Inc. returned −21.2% against +16.2% for the S&P 500, dividends included.

BBNX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26BBNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BBNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Beta Bionics, Inc. (BBNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.3×

Cheaper than 94% of US stocks

Price / sales
8.4×

Cheaper than 16% of US stocks

Price / book
3.3×

Cheaper than 29% of US stocks

EV / EBITDA
−8.2×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
37.8%

Higher than 82% of US stocks

Earnings growth (YoY)
37.8%

Higher than 70% of US stocks

Gross margin
59.0%

Higher than 72% of US stocks

Operating margin
−79.9%

Higher than 15% of US stocks

Net margin
−61.3%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−26.2%

Higher than 29% of US stocks

Return on assets
−16.7%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Beta Bionics, Inc. (BBNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Beta Bionics, Inc. has a market value of $1.0B and an enterprise value of $664.2M.

  • Revenue in the twelve months to 30 June 2026: $119.0M. The latest quarter grew 37.8% year on year.

  • Net income over the same four quarters: −$73.0M, a −61.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.65.

  • Free cash flow in the twelve months to 30 June 2026: −$61.4M.

  • Shares outstanding: 45.0M.

  • Trailing P/E: −10.3×; forward P/E: −8.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Beta Bionics, Inc. employs 420 people — $283K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

BBNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BBNXBeta Bionics, Inc.$1.0B
37
LMRILumexa Imaging Holdings, Inc.$976.9M
2
CBLLCeribell, Inc.$858.8M
38
QDELQuidelOrtho Corp.$846.3M
33
ENOVEnovis Corp.$998.8M
77
PRCTPROCEPT BioRobotics Corp.$1.0B
36
SIBNSI-BONE, Inc.$833.0M
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Beta Bionics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBNX news & analysis

BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

PRNewsWire · 8 Oct 2026negative

Rosen Law Firm reminded Beta Bionics common stock purchasers from July 30, 2025, through February 24, 2026, that the deadline to seek lead plaintiff status in a securities fraud lawsuit is November 3, 2026. The notice says eligible purchasers may be entitled to compensation through a contingency fee arrangement without out-of-pocket fees or costs.

Why it matters — The notice concerns a securities fraud lawsuit involving BBNX and sets a lead plaintiff deadline for investors who purchased shares during the stated class period.

Kaplan Fox Encourages Beta Bionics, Inc. (BBNX) Investors Seeking Recovery to Contact the Firm Before November 3, 2026

Newsfile Corp · 8 Oct 2026negative

Kaplan Fox & Kilsheimer LLP said a class action lawsuit has been filed against Beta Bionics on behalf of investors who acquired its common stock from July 30, 2025, through February 24, 2026. The firm invited investors who suffered losses to contact it before November 3, 2026.

Why it matters — The lawsuit and related investor outreach concern BBNX shareholders who acquired common stock during the specified period.

Kirby McInerney LLP Alerts Investors Who Acquired Beta Bionics, Inc. BBNX Securities Between July 30, 2025 and February 24, 2026 of Pending Lawsuit

Business Wire · 8 Oct 2026negative

Kirby McInerney LLP says investors who acquired Beta Bionics securities between July 30, 2025, and February 24, 2026, may contact the firm regarding a pending federal securities class action. The firm cites November 3, 2026, as the deadline to seek appointment as lead plaintiff.

Why it matters — The notice concerns pending securities litigation involving BBNX and a deadline for investors seeking the lead-plaintiff role.

Deadline Alert: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

GlobeNewsWire · 7 Oct 2026negative

Glancy Prongay Wolke & Rotter LLP reminded investors that November 3, 2026 is the deadline to file a lead plaintiff motion in a securities class action involving Beta Bionics. The action covers investors who acquired BBNX securities from July 30, 2025, through February 24, 2026.

Why it matters — The notice concerns pending securities litigation and a lead plaintiff deadline affecting investors who held BBNX during the stated class period.

Kaplan Fox Alerts Beta Bionics, Inc. (BBNX) Investors to a Securities Fraud Lawsuit - Lead Plaintiff Deadline is November 3, 2026

Newsfile Corp · 7 Oct 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Beta Bionics on behalf of investors who acquired the company’s common stock from July 30, 2025, through February 24, 2026. The announcement states that the lead plaintiff deadline is November 3, 2026.

Why it matters — The lawsuit and stated deadline are developments investors following BBNX may wish to monitor.

FAQ

Frequently asked questions about BBNX stock

What is the BBNX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Beta Bionics, Inc. have a median 12-month price target of $24, with estimates ranging from $16 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBNX stock a buy right now?

Of the 13 analysts covering Beta Bionics, Inc., 9 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beta Bionics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBNX?

As at 8 Oct 2026, Beta Bionics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will BBNX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +34.8% from the last close, and Ticker Nerd's factor model ranks Beta Bionics, Inc. 37 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBNX stock forecast for 2030?

No analyst covering Beta Bionics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $30 over the next 12 months.

How has BBNX stock performed over the past year?

Beta Bionics, Inc. returned -21.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Beta Bionics, Inc. do?

Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes.

What is the latest news on BBNX?

The most recent item we track (PRNewsWire, 8 Oct 2026): "BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit". Rosen Law Firm reminded Beta Bionics common stock purchasers from July 30, 2025, through February 24, 2026, that the deadline to seek lead plaintiff status in a securities fraud lawsuit is November 3, 2026. The notice says eligible purchasers may be entitled to compensation through a contingency fee arrangement without out-of-pocket fees or costs.

Company

About Beta Bionics, Inc.

Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes. Its core product, the iLet Bionic Pancreas, is designed to simplify day-to-day diabetes management by using adaptive closed-loop algorithms to determine insulin dosing. Beta Bionics offers systems and related solutions for adults and children with type 1 diabetes, alongside supporting software and connected tools that help streamline treatment workflows. The company operates in the diabetes technology and medical devices markets, where it addresses the needs of patients, caregivers, and healthcare providers seeking more integrated insulin management solutions. Headquartered in Irvine, California, Beta Bionics plays a role in advancing device-based diabetes care through commercially available products centered on automated insulin delivery.

CEO Mr. Sean T. Saint PE · 420 employees · United States · https://www.betabionics.com